Now showing items 1-1 of 1
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
(Cancer Med, 2013-06)
Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog ...